⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 10, 2024Open Access

Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosis

Indrani Datta Insha Zahoor Nasar Ata Faraz Rashid Mirela Cerghet Ramandeep Rattan Laila Poisson Shailendra Giri

View Full Paper

Ask AI

Bookmark

Share

Abstract

Multiple sclerosis (MS) is the most common inflammatory neurodegenerative disease of the central nervous system (CNS) in young adults and results in progressive neurological defects. The relapsing-remitting phenotype (RRMS) is the most common disease course in MS and may progress to the progressive form (PPMS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Datta et al. (2024) studied this question.

synapsesocial.com/papers/68e79ac4b6db64358770ad35 https://doi.org/10.1101/2024.02.07.579252

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Utility of an Untargeted Metabolomics Approach Using a 2D GC-GC-MS Platform to Distinguish Relapsing and Progressive Multiple Sclerosis2024 · 9 citations
2Utility of an untargeted metabolomics approach using a 2D GC-GC‒MS platform to distinguish relapsing and progressive multiple sclerosis2024
3Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course MonitoringOriginal Research · 2018 · 68 citations
4NMR-based metabolomics identification of potential serum biomarkers of disease progression in patients with multiple sclerosis2024 · 15 citations
5Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives—A Systematic Review2025 · 13 citations